SCHEMBL3977039

SCHEMBL3977039

CC1(C)CC=C(c2nc(C3(O)CCOCC3)ccc2C(N)=O)CC1

nearest known ligand 0.54

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
TBK1 Q9UHD2 1/20 0.36
CSF1R P07333 5/20 0.33
KDM5B Q9UGL1 1/20 0.32
KIT P10721 1/20 0.31
FLT3 P36888 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3980584 0.90 KDM5B (0.35) TBK1CSF1RKDM5BKITFLT3
SCHEMBL3977044 0.85 TBK1 (0.34) TBK1CSF1RKDM5BKITFLT3
SCHEMBL3973510 0.84 TBK1 (0.34) TBK1CSF1RKITFLT3
SCHEMBL3977366 0.82 TBK1 (0.32) TBK1CSF1RKDM5BKIT
SCHEMBL16320663 0.80 CSF1R (0.33) TBK1CSF1RKIT
SCHEMBL3981168 0.80 CSF1R (0.35) TBK1CSF1RKDM5BKITFLT3
SCHEMBL16320574 0.79 CCNA2 (0.40) TBK1CSF1RKDM5BKIT
SCHEMBL3089974 0.78 KDM5B (0.38) TBK1CSF1RKDM5BKITFLT3
SCHEMBL3081410 0.77 TBK1 (0.37) TBK1CSF1RKDM5BKITFLT3
SCHEMBL3164430 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9394289-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-07-19 US disclosed
EP-2016070-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-01-13 EP disclosed
US-20140378457-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-12-25 US disclosed
US-8859602-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2014-10-14 US disclosed
EP-2016070-A1 INHIBITORS OF C-FMS KINASE Janssen Pharmaceutica, N.V. (BE) 2009-01-21 EP disclosed
WO-2007124319-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 WO disclosed
US-20070249680-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378457-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES TBK1 1205/4885CSF1R 59/4885KDM5B 1516/4885
US-20070249680-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES TBK1 1205/4885CSF1R 59/4885KDM5B 1516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.